Skip to main content

68ga-psma-11

Generic: gozetotide

68ga-psma-11: 7 clinical trials tracked.

68ga-psma-11 evidence translation

What we can confirm

7 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about 68ga-psma-11, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 2 study sponsors
Clinical Trials (7)

Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery

NCT07674771·Early Phase 1
Not yet recruiting

Primary endpoint: Reduction in PSMA-positive TTV

Interventionalopen30 targetStarted 2026-10Completion 2029-061 site · United StatesUniversity of Texas Southwestern Medical Center

A Single Arm, Multicenter, Prospective, Open Label, Longitudinal Phase 3 Study of Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) Combined With Magnetic Resonance Imaging (MRI) Compared to Standard of Care (SOC) for the Detection of Prostate Cancer (PCa).

NCT07052214·Phase 3·TLX
Recruiting

Primary endpoint: Primary Objective

Interventionalopen338 targetStarted 2025-08Completion 2027-0418 sites · Australia, United StatesTelix Pharmaceuticals (Innovations) Pty Limited

An Open-label Dosimetry, Biodistribution, Tolerability and Safety Study of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Moderately and Severely Impaired and With Normal Renal Function.

NCT06004661·Phase 2·NVS
Active, not recruiting

Primary endpoint: Absorbed radiation dose in kidneys and selected organs

Interventionalopen23 enrolledStarted 2024-04Completion 2026-129 sites · France, Germany, Italy, Spain…Novartis Pharmaceuticals

A Prospective, Open-label, Multi-center, Single-arm, Phase II Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT05670106·Phase 2·NVS
Completed

Primary endpoint: Main part: Confirmed Overall Response Rate (ORR) per Blinded Independent Central Review (BICR)

Interventionalopen62 enrolledStarted 2023-05Completion 2026-0417 sites · ChinaNovartis Pharmaceuticals

Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer

NCT04886986·Phase 1
Recruiting

Primary endpoint: Dose limiting toxicity (DLT) of 225Ac-J591 and 177Lu-PSMA small molecule

Interventionalopen42 targetStarted 2021-06Completion 2029-122 sites · United StatesWeill Medical College of Cornell University

PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer

NCT04689828·Phase 3·NVS
Active, not recruiting

Primary endpoint: Radiographic Progression Free Survival (rPFS)

InterventionalRandomizedopen469 enrolledStarted 2021-06Completion 2026-0950 sites · Austria, Belgium, Canada, Czechia…Novartis Pharmaceuticals

An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT04720157·Phase 3·NVS
Active, not recruiting

Primary endpoint: Radiographic Progression Free Survival (rPFS)

InterventionalRandomizedopen1,140 targetStarted 2021-06Completion 2027-0250 sites · United StatesNovartis Pharmaceuticals